Last reviewed · How we verify
Extended release torsemide
Torsemide is a loop diuretic that works by inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of the loop of Henle in the kidneys.
Torsemide is a loop diuretic that works by inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of the loop of Henle in the kidneys. Used for Hypertension, Edema.
At a glance
| Generic name | Extended release torsemide |
|---|---|
| Sponsor | Sarfez Pharmaceuticals, Inc. |
| Drug class | Loop diuretic |
| Target | NKCC2 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
This inhibition leads to increased excretion of sodium, chloride, and water, resulting in decreased blood volume and pressure. Torsemide has a longer duration of action compared to other loop diuretics due to its extended release formulation.
Approved indications
- Hypertension
- Edema
Common side effects
- Hypotension
- Dehydration
- Electrolyte imbalance
Key clinical trials
- Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder (PHASE2)
- Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (PHASE4)
- Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone (PHASE3)
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (PHASE3)
- Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects (PHASE3)
- A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects (PHASE3)
- A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs (PHASE4)
- Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extended release torsemide CI brief — competitive landscape report
- Extended release torsemide updates RSS · CI watch RSS
- Sarfez Pharmaceuticals, Inc. portfolio CI